Sun Pharma launches website for its long-term care division
The new website presents Sun Pharma's LTC portfolio of alternative formulation products and underscores Sun Pharma's commitment to meeting the needs of the up to 40% of American adults who cannot or will not swallow solid medication forms.
Sun Pharma's LTC portfolio includes the first and only U.S. Food and Drug Administration (FDA)- approved extended-release sprinkle formulation of metoprolol succinate; the first and only FDA approved sprinkle formulation of delayed-release duloxetine; and the first and only approved sprinkle formulation of rosuvastatin, Ezallor Sprinkle (rosuvastatin) immediate-release capsules. The Ezallor Sprinkle label was recently updated to allow for sprinkling the capsule contents over pudding (in addition to applesauce) as a soft-food alternative mode of administration.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content